UCB Pharma has launched two new strengths of Neupro (rotigotine) transdermal patches 1mg/24hr and 3mg/24hr. These additional strengths can be used alongside the existing 2mg/24hr patch in the management of moderate to severe idiopathic restless legs syndrome.
Treatment should be initiated using a 1mg/24hr patch daily and increased according to patient response in weekly increments of 1mg/24hr until an effective dose is reached or the maximal dose of 3mg/24hr is reached.
The need for treatment continuation should be reconsidered every six months.
The mechanism of action for rotigotine in restless legs syndrome is not fully understood.
Further information: UCB Pharma